1592. Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine Among People with HIV with Detectable Viral Loads at Initiation: Trio Cohort Study

BACKGROUND: Cabotegravir+Rilpivirine (CAB+RPV) is the first FDA-approved complete long-acting (LA) injectable antiretroviral therapy (ART) for treatment of HIV-1 infection among ART-experienced, virologically suppressed (VL < 50 c/mL) people with HIV (PWH). We assessed utilization and effectivene...

Descripción completa

Detalles Bibliográficos
Autores principales: Elion, Rick A, Frick, Andrew, Radtchenko, Janna, Sridhar, Gayathri, Sarkar, Supriya, Eron, Joseph J, Mounzer, Karam, van Wyk, Jean A, Vannappagari, Vani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677310/
http://dx.doi.org/10.1093/ofid/ofad500.1427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677310/
http://dx.doi.org/10.1093/ofid/ofad500.1427

Ejemplares similares